Linezolid in the treatment of periprosthetic joint infection caused by coagulase-negative staphylococci

References

• Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645–1654.
   PubMed Web of Science ®Google Scholar
• von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis. 2002;2:677–685.
   PubMed Web of Science ®Google Scholar
• Peel TN, Buising KL, Choong PF. Prosthetic joint infection: challenges of diagnosis and treatment. ANZ J Surg. 2011;81:32–39.
   PubMed Web of Science ®Google Scholar
• Kutscha-Lissberg F, Hebler U, Muhr G, et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2003;47:3964–3966.
   PubMed Web of Science ®Google Scholar
• Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis. 2007;59:173–179.
   PubMed Web of Science ®Google Scholar
• Morata L, Senneville E, Bernard L, et al. A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther. 2014;3:235–243.
   PubMedGoogle Scholar
• Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther. 2006;28:1155–1163.
   PubMed Web of Science ®Google Scholar
• Soriano A, Gomez J, Gomez L, et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis. 2007;26:353–356.
   PubMed Web of Science ®Google Scholar
• Rao N, Ziran BH, Wagener MM, et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004;38:1058–1064.
   PubMed Web of Science ®Google Scholar
• Cobo J, Lora-Tamayo J, Euba G, et al. Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria. Diagn Microbiol Infect Dis. 2013;76:93–98.
   PubMed Web of Science ®Google Scholar
• Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis. 2003;37:1389–1391.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande L, Streit JM, et al. ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. J Antimicrob Chemother. 2018;73:1880–1887.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Streit JM, et al. ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries. J Antimicrob Chemother. 2017;72:3093–3099.
   PubMed Web of Science ®Google Scholar
• Lourtet-Hascoët J, Félicé MP, Bicart-See A, et al. Species and antimicrobial susceptibility testing of coagulase-negative staphylococci in periprosthetic joint infections. Epidemiol Infect. 2018;146:1–6.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vitale F, Melica G, et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005;55:387–390.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE); [cited 2018 Jul 15]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Vasso M, Schiavone-Panni A, De Martino I, et al. Prosthetic knee infection by resistant bacteria: the worst-case scenario. Knee Surg Sports Traumatol Arthrosc. 2016;24:3140–3146.
   PubMed Web of Science ®Google Scholar
• Cunningham DJ, Kavolus JJ, Bolognesi MP, et al. Specific infectious organisms associated with poor outcomes in treatment for hip periprosthetic infection. J Arthroplasty. 2017;32:1984–1990.e5.
   PubMed Web of Science ®Google Scholar
• Sisson TL, Jungbluth GL, Hopkins NK. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol. 1999;39:1277–1282.
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45:1843–1846.
   PubMed Web of Science ®Google Scholar
• Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002;50:73–77.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Martínez JM, Ballesta S, García I, et al. Activity and penetration of linezolid and vancomycin against Staphylococcus epidermidis biofilms. Enferm Infecc Microbiol Clin. 2007;25:425–428.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41:586–589.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481–1490.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Di Biagio A, Cenderello G, et al. Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect. 2001;43:148–149.
   PubMed Web of Science ®Google Scholar
• Crockarell JR, Hanssen AD, Osmon DR, et al. Treatment of infection with debridement and retention of the components following hip arthroplasty. J Bone Joint Surg Am. 1998;80:1306–1313.
   PubMed Web of Science ®Google Scholar
• Byren I, Bejon P, Atkins BL, et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother. 2009;63:1264–1271.
   PubMed Web of Science ®Google Scholar
• Silva M, Tharani R, Schmalzried TP. Results of direct exchange or debridement of the infected total knee arthroplasty. Clin Orthop Relat Res. 2002;404:125–131.
   Google Scholar
• Deirmengian C, Greenbaum J, Lotke PA, et al. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. J Arthroplasty. 2003;18:22–26.
   PubMed Web of Science ®Google Scholar
• Mont MA, Waldman B, Banerjee C, et al. Multiple irrigation, debridement, and retention of components in infected total knee arthroplasty. J Arthroplasty. 1997;12:426–433.
   PubMed Web of Science ®Google Scholar
• Jämsen E, Stogiannidis I, Malmivaara A, et al. Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop. 2009;80:67–77.
   PubMed Web of Science ®Google Scholar
• Marculescu CE, Cantey JR. Polymicrobial prosthetic joint infections: risk factors and outcome. Clin Orthop Relat Res. 2008;466:1397–1404.
   PubMed Web of Science ®Google Scholar
• Betsch BY, Eggli S, Siebenrock KA, et al. Treatment of joint prosthesis infection in accordance with current recommendations improves outcome. Clin Infect Dis. 2008;46:1221–1226.
   PubMed Web of Science ®Google Scholar
• Gehrke T, Alijanipour P, Parvizi J. The management of an infected total knee arthroplasty. Bone Joint J. 2015;97-B:20–29.
   PubMedGoogle Scholar
• Wolf M, Clar H, Friesenbichler J, et al. Prosthetic joint infection following total hip replacement: results of one-stage versus two-stage exchange. Int Orthop. 2014;38:1363–1368.
   PubMedGoogle Scholar
• French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51(Suppl. 2):ii45–ii53.
   PubMedGoogle Scholar
• Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc. 2004;79:1137–1144.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy. 2001;21:1010–1013.
   PubMed Web of Science ®Google Scholar
• Huerta C, Garcia RL. Risk of clinical blood dyscrasia in a cohort of antibiotic users. Pharmacotherapy. 2002;22:630–636.
   PubMed Web of Science ®Google Scholar
• Itani KM, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199:804–816.
   PubMed Web of Science ®Google Scholar
• Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68:2128–2133.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67:034–042.
   Web of Science ®Google Scholar
• Widerström M, Wiström J, Edebro H, et al. Colonization of patients, healthcare workers, and the environment with healthcare-associated Staphylococcus epidermidis genotypes in an intensive care unit: a prospective observational cohort study. BMC Infect Dis. 2016;16:743.
   PubMed Web of Science ®Google Scholar
• Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect. 2003;9:1179–1186.
   PubMed Web of Science ®Google Scholar
• Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27:870–926.
   PubMed Web of Science ®Google Scholar
• Kuiper JW, Vos SJ, Saouti R, et al. Prosthetic joint-associated infections treated with DAIR (debridement, antibiotics, irrigation, and retention): analysis of risk factors and local antibiotic carriers in 91 patients. Acta Orthop. 2013;84:380–386.
   PubMed Web of Science ®Google Scholar
• Urish KL, Bullock AG, Kreger AM, et al. A multicenter study of irrigation and debridement in total knee arthroplasty periprosthetic joint infection: treatment failure is high. J Arthroplasty. 2018;33:1154–1159.
   PubMed Web of Science ®Google Scholar